CONMED VP granted 5,896 RSUs in equity award

CONMED Corp reported that VP Corporate Controller Andrew James Moller acquired 5,896 restricted stock units (RSUs) as a grant of equity compensation.

Rhea-AI Filing Summary

CONMED Corp reported that VP Corporate Controller Andrew James Moller acquired 5,896 restricted stock units (RSUs) as a grant of equity compensation. Each RSU represents a contingent right to receive one share of CONMED common stock. The RSUs generally vest over three years, with 33% vesting after one year, another 33% after two years, and the remaining 34% after three years, subject to the terms of the company’s 2025 Long-Term Incentive Plan.

Insider Trade Summary

Grant/Award: 5,896 shares

Grant/Award 1 txn

Insider Moller Andrew James

Role VP Corporate Controller

Type	Security	Shares	Price	Value
Grant/Award	RSUs (Restricted Stock Units)	5,896	$0.00	$0.00

Holdings After Transaction: RSUs (Restricted Stock Units) — 5,896 contracts (Direct)

Footnotes (1)

1. F1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of CONMED Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting over a three-year period with the first 33% of the RSUs vesting one year after the grant date, 33% second year and 34% third year.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CONMED Corp (CNMD) report for Andrew James Moller?

CONMED reported that VP Corporate Controller Andrew James Moller received a grant of 5,896 restricted stock units. These RSUs are equity-based compensation that may convert into CONMED common shares over time, subject to vesting conditions under the 2025 Long-Term Incentive Plan.

How many RSUs did CONMED’s VP Corporate Controller receive in this Form 4 filing?

Andrew James Moller received 5,896 restricted stock units according to the Form 4. This entire amount reflects a new grant, and his direct holdings in this RSU award total 5,896 units following the reported transaction on March 2, 2026.

Are the RSUs granted to CONMED’s Andrew James Moller immediately vested?

The RSUs are not immediately vested; they generally vest over three years. About 33% vests one year after the grant date, another 33% in the second year, and 34% in the third year, subject to the 2025 Long-Term Incentive Plan terms.

What does each RSU granted to Andrew James Moller at CONMED Corp represent?

Each restricted stock unit represents a contingent right to receive one share of CONMED common stock. The actual delivery of shares depends on satisfying vesting conditions specified in the company’s 2025 Long-Term Incentive Plan over the three-year schedule.

Was there any purchase price for the RSUs granted to Andrew James Moller at CONMED?

The Form 4 shows a transaction price per RSU of $0.0000, reflecting that the units were granted as compensation rather than purchased in the market. This indicates a non-cash equity award under the company’s long-term incentive program.

What plan governs the RSU grant reported for CONMED Corp (CNMD) in this Form 4?

The RSU grant is governed by CONMED’s 2025 Long-Term Incentive Plan. This plan sets the terms and conditions for vesting and settlement of the restricted stock units, including the three-year vesting schedule described in the Form 4 footnote.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/04/2026 - 03:50 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Moller Andrew James

(Last) (First) (Middle)

C/O CONMED CORPORATION

11311 CONCEPT BOULEVARD

(Street)

LARGO FL 33773

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CONMED Corp [ CNMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP Corporate Controller

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
RSUs (Restricted Stock Units)	$0	03/02/2026		A		5,896		(1)	03/02/2036	Common Stock	5,896	$0	5,896	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of CONMED Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting over a three-year period with the first 33% of the RSUs vesting one year after the grant date, 33% second year and 34% third year.

	/s/ Thomas Fistek for Andrew James Moller by Power of Attorney	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.